system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: UNASSIGNED. Meshes: Binding Sites, CRISPR-Cas Systems, Chromatin, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Histone-Lysine N-Methyltransferase, Homeodomain Proteins, Humans, Leukemia, Myeloid, Acute, Methyltransferases, Mutation, Myeloid Ecotropic Viral Integration Site 1 Protein, Myeloid-Lymphoid Leukemia Protein, Neoplasm Proteins, Nuclear Proteins, Proto-Oncogene Proteins, fms-Like Tyrosine Kinase 3.
user
Does targeting Chromatin Regulators inhibit Leukemogenic Gene Expression in NPM1 Mutant Leukemia? Context: Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3 are frequently highly expressed and mutated in acute myeloid leukemia (AML). Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in the Nucleophosmin (NPM1) gene, and FLT3 is concomitantly mutated in approximately 60% of these cases. Little is known about how mutant NPM1 (NPM1
assistant
MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1 Final Decision: yes